MA38042A3 - Méthylglyoxal en tant que marqueur du cancer - Google Patents

Méthylglyoxal en tant que marqueur du cancer

Info

Publication number
MA38042A3
MA38042A3 MA38042A MA38042A MA38042A3 MA 38042 A3 MA38042 A3 MA 38042A3 MA 38042 A MA38042 A MA 38042A MA 38042 A MA38042 A MA 38042A MA 38042 A3 MA38042 A3 MA 38042A3
Authority
MA
Morocco
Prior art keywords
methylglyoxal
cancer
marker
cells
tissues
Prior art date
Application number
MA38042A
Other languages
English (en)
Other versions
MA38042B2 (fr
MA38042A2 (fr
Inventor
Dominique Belpomme
Philippe Irigaray
Original Assignee
Association Pour La Rech Therapeutique Anti Cancereuse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Association Pour La Rech Therapeutique Anti Cancereuse filed Critical Association Pour La Rech Therapeutique Anti Cancereuse
Publication of MA38042A2 publication Critical patent/MA38042A2/fr
Publication of MA38042A3 publication Critical patent/MA38042A3/fr
Publication of MA38042B2 publication Critical patent/MA38042B2/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates

Abstract

L'invention concerne un test de diagnostic et de pronostic du cancer fiable, sensible et facile à manipuler, par la mesure et l'analyse de la production de méthylglyoxal (mg) à partir de cellules cancéreuses métaboliquement actives ; dans des échantillons biologiques de fluides extracellulaires, de cellules et/ou de tissus de sujets humains ou animaux. L'invention utilise n'importe quel procédé
MA38042A 2012-10-25 2013-10-25 Méthylglyoxal en tant que marqueur du cancer MA38042B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/071163 WO2014063743A1 (fr) 2012-10-25 2012-10-25 Méthylglyoxal en tant que marqueur du cancer
PCT/EP2013/072459 WO2014064283A1 (fr) 2012-10-25 2013-10-25 Méthylglyoxal en tant que marqueur du cancer

Publications (3)

Publication Number Publication Date
MA38042A2 MA38042A2 (fr) 2017-02-28
MA38042A3 true MA38042A3 (fr) 2018-03-30
MA38042B2 MA38042B2 (fr) 2019-11-29

Family

ID=47074733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38042A MA38042B2 (fr) 2012-10-25 2013-10-25 Méthylglyoxal en tant que marqueur du cancer

Country Status (11)

Country Link
US (1) US20150301056A1 (fr)
JP (1) JP6543193B2 (fr)
CN (1) CN104854458B (fr)
CA (1) CA2889110A1 (fr)
DK (1) DK2912465T3 (fr)
ES (1) ES2656896T3 (fr)
MA (1) MA38042B2 (fr)
PT (1) PT2912465T (fr)
RU (1) RU2666255C2 (fr)
TN (1) TN2015000161A1 (fr)
WO (2) WO2014063743A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106769349B (zh) * 2017-01-06 2020-01-21 上海君联医疗设备有限公司 血液中异常糖基化蛋白细胞的检测方法
CN108426996B (zh) * 2017-02-15 2020-09-15 江苏美正生物科技有限公司 一种3-甲基喹噁啉-2-羧酸残留的快速检测试剂盒及其制备方法和应用
GB2566681B (en) * 2017-09-14 2021-07-28 Ip2Ipo Innovations Ltd Biomarker
CN108061802A (zh) * 2017-12-08 2018-05-22 武汉科技大学 一种通过血液检测评定乳腺癌的方法
US20220050109A1 (en) * 2018-11-18 2022-02-17 National University Of Singapore Method of detecting cancer and/or tuberculosis
CN110604823B (zh) * 2019-10-21 2020-10-20 兰州大学 一种快速筛选抗糖化和/或抗衰老物质的方法
CN113376199A (zh) * 2021-05-12 2021-09-10 兰立生物科技(苏州)有限公司 一种用于癌症检测的生化分析检测系统
CN114496306B (zh) * 2022-01-28 2022-12-20 北京大学口腔医学院 基于机器学习的预后生存阶段预测方法和系统
US20220206017A1 (en) * 2022-03-18 2022-06-30 Joel Steven Goldberg Aerobic glycolysis and hypermetabolic states

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
US8026049B2 (en) * 2007-03-23 2011-09-27 Wisconsin Alumni Research Foundation Noninvasive measurement and identification of biomarkers in disease state
JP4836926B2 (ja) * 2007-11-12 2011-12-14 株式会社日本トリム 糖分解代謝物の測定方法
JP5787339B2 (ja) * 2009-12-28 2015-09-30 学校法人福岡大学 糖尿病前症の検査方法
CA2828119A1 (fr) * 2011-02-24 2012-08-30 Vermillion, Inc. Panel de marqueurs biologiques, procedes de diagnostic et necessaires d'essais pour le cancer de l'ovaire

Also Published As

Publication number Publication date
JP2016500821A (ja) 2016-01-14
WO2014063743A1 (fr) 2014-05-01
RU2015119512A (ru) 2016-12-20
JP6543193B2 (ja) 2019-07-10
DK2912465T3 (en) 2018-01-15
CN104854458A (zh) 2015-08-19
ES2656896T3 (es) 2018-02-28
CN104854458B (zh) 2018-02-09
RU2666255C2 (ru) 2018-09-06
PT2912465T (pt) 2018-01-25
TN2015000161A1 (en) 2016-10-03
CA2889110A1 (fr) 2014-05-01
US20150301056A1 (en) 2015-10-22
WO2014064283A1 (fr) 2014-05-01
MA38042B2 (fr) 2019-11-29
MA38042A2 (fr) 2017-02-28

Similar Documents

Publication Publication Date Title
MA38042A3 (fr) Méthylglyoxal en tant que marqueur du cancer
BR112012016572A2 (pt) aparelho e método para medição não invasiva "in vivo" por meio de espectroscopia raman de glicose presente no fluido intersticial na pele de um indivíduo, e, peça de mão
EA201590686A1 (ru) Тест на митохондриальную токсичность
IN2014MN02060A (fr)
BR112017014694A2 (pt) sistema, dispositivo, monitor, faixa de sensores e método para a medição de função autonômica para o diagnóstico e a validação de tratamentos e resultados de paciente
EA201390150A1 (ru) Способы выявления сигнатур заболевания или патологических состояний в текучих средах организма
Bikowski et al. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton
BR112015026222A2 (pt) dispositivo de coleta de amostra de fluido biológico
BRPI0709271B8 (pt) métodos para a detecção de uma doença renal
BR112016004320A2 (pt) biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste
WO2012065117A3 (fr) Diagnostics hors laboratoire de cancer de la bouche
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
GB2515713A (en) Methods, packaging and apparatus for collection of biological samples
BR112014015424A2 (pt) detecção de células derivadas de tecido do cordão umbilical humano
Hopper et al. Falsely increased plasma lactate concentration due to ethylene glycol poisoning in 2 dogs
BR112014021173A2 (pt) Teste diagnóstico da resistência à azacitidina
WO2012109258A3 (fr) Compositions et procédés de surveillance d'oxalate
PL407244A1 (pl) Bioczujnik elektrochemiczny do wykrywania białka S100B
RU2014135019A (ru) Способ диагностики меланомы хориоидеи
BR112018076005A2 (pt) anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral
RU2011133485A (ru) Способ экспресс-диагностики бронхолегочных заболеваний
WO2012047637A3 (fr) Dosages et procédés destinés à déterminer le risque de développer une maladie médiée par les macrophages chez un sujet infecté par le vih
WO2012178030A3 (fr) Mesure précise de glutathion dans le diagnostic de maladies et le criblage de métabolites de médicament
Wang Dr. Yang Wang